» Articles » PMID: 36010930

Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150

Abstract

The IMbrave150 trial demonstrated the high efficacy and safety of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma (HCC). In this multicenter study, the efficacy of this combination and its effect on liver functional reserve were evaluated in patients not meeting the eligibility criteria of IMbrave150. Of 115 patients with unresectable HCC treated with atezolizumab and bevacizumab between October 2020 and January 2022, 72 did not meet the eligibility criteria of IMbrave150, most frequently due to a history of systemic therapy (60/72), platelet counts < 75 × 109/L (7/72), Child-Pugh B (9/72), and 2+ proteinuria (8/72). Atezolizumab and bevacizumab therapy was equally effective for patients who did or did not meet the eligibility criteria (PFS, 6.5 vs. 6.9 months, p = 0.765), consistent with subgroup analyses of histories of systemic therapy, platelet counts, Child-Pugh, and proteinuria. Baseline ALBI scores were worse in patients who did not meet the criteria than in those who did and significantly worsened after treatment initiation in patients not meeting the criteria (baseline vs. 12 weeks; 2.35 ± 0.43 vs. −2.18 ± 0.54; p = 0.007). Accordingly, atezolizumab plus bevacizumab was effective for patients not meeting the eligibility criteria of IMbrave150, although careful monitoring for changes in liver functional reserve is needed.

Citing Articles

Validation of an albumin-indocyanine green-based China liver cancer staging system to evaluating resectable hepatocellular carcinoma patients and comparison with the Child-Pugh-based China liver cancer staging system.

Chen M, Ren C, Wang M, Yu M, Wu B, Zhuang B Front Oncol. 2025; 15:1450333.

PMID: 40052123 PMC: 11882571. DOI: 10.3389/fonc.2025.1450333.


Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis.

Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G Liver Cancer. 2024; 13(3):227-237.

PMID: 38756146 PMC: 11095597. DOI: 10.1159/000533991.


Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.

Singal A, Ozgurdal K, Fan X, Vassilev Z, Pan X, Multani J Cancers (Basel). 2023; 15(23).

PMID: 38067235 PMC: 10705135. DOI: 10.3390/cancers15235532.


Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy.

Navadurong H, Prasoppokakorn T, Siriwong N, Phathong C, Teeyapun N, Tanasanvimon S World J Gastrointest Oncol. 2023; 15(10):1771-1783.

PMID: 37969413 PMC: 10631433. DOI: 10.4251/wjgo.v15.i10.1771.


Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

Kulkarni A, Tevethia H, Kumar K, Premkumar M, Muttaiah M, Hiraoka A EClinicalMedicine. 2023; 63:102179.

PMID: 37680945 PMC: 10480543. DOI: 10.1016/j.eclinm.2023.102179.


References
1.
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

2.
Kudo M . Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass. Liver Cancer. 2022; 11(3):185-191. PMC: 9218634. DOI: 10.1159/000524977. View

3.
Brahmer J, Lacchetti C, Schneider B, Atkins M, Brassil K, Caterino J . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(17):1714-1768. PMC: 6481621. DOI: 10.1200/JCO.2017.77.6385. View

4.
Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J . Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res. 2022; 52(9):773-783. DOI: 10.1111/hepr.13797. View

5.
Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View